Search | Clinical Trials Finder

Conditions: Cystic Fibrosis
Interventions: VX-445/TEZ/IVA, TEZ/IVA, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 28
States / cities: Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 24 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Carfilzomib, Dexamethasone, Pomalidomide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Denver, Colorado • New Haven, Connecticut + 8 more

Conditions: Triple Negative Breast Neoplasms
Interventions: 350 mg leronlimab, 525 mg leronlimab, 700 mg leronlimab, AUC 5 Carboplatin, Maximum Tolerated Dose (MTD) of leronlimab; Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: San Francisco, California • Chicago, Illinois

Conditions: Type 2 Diabetes Mellitus
Interventions: 2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Oropharynx Squamous Cell Carcinoma
Interventions: vidutolimod, cemiplimab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 17 more

Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Interventions: Paclitaxel, CB-839; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 25
States / cities: Birmingham, Alabama • Mobile, Alabama • New Haven, Connecticut + 20 more

Conditions: Solid Tumor, Adult
Interventions: FT516, Avelumab, Cyclophosphamide, Fludarabine, IL-2; Drug
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Hackensack, New Jersey • Houston, Texas

Conditions: Breast Cancer
Interventions: Temsirolimus, Neratinib; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 4
States / cities: Goodyear, Arizona • Los Angeles, California • New York, New York

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more

Conditions: Advanced Malignancies, Metastatic Cancer
Interventions: INCAGN01876, Nivolumab, Ipilimumab; Drug
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 15
States / cities: Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more

Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor
Interventions: RLY-5836, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib; Drug
Lead sponsor: Relay Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Orlando, Florida • Indianapolis, Indiana • Boston, Massachusetts + 4 more

Conditions: Hypertension
Interventions: Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo; Drug
Lead sponsor: George Medicines PTY Limited; Industry
Eligibility: 18 Years and older
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 23
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more

Conditions: Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions: XL102, Fulvestrant, Abiraterone, Prednisone; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more

Conditions: Cystic Fibrosis
Interventions: Initiation of CFTR Modulator, Hyperpolarized Xenon 129; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 21 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Triple-negative Breast Cancer
Interventions: AE37 Peptide vaccine, Pembrolizumab; Biological
Lead sponsor: NuGenerex Immuno-Oncology; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 6
States / cities: Decatur, Illinois • Effingham, Illinois • Swansea, Illinois + 3 more

Conditions: Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions: Axillary Lymph Node Dissection, Enzalutamide, Laboratory Biomarker Analysis, Lymph Node Biopsy, Paclitaxel, Therapeutic Conventional Surgery; Procedure · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Acute Lymphoblastic Leukemia (ALL)
Interventions: Carfilzomib, Dexamethasone, Mitoxantrone, PEG-asparaginase, Vincristine, Intrathecal (IT) Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-Mercaptopurine, Cyclophosphamide, Cytarabine, Daunorubicin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 1 Month to 21 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 22
States / cities: Oakland, California • Orange, California • Aurora, Colorado + 19 more

Conditions: HIV Infections
Interventions: MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs; Drug
Lead sponsor: Myrexis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: HIV Infections
Interventions: Lamivudine/zidovudine, Efavirenz, Raltegravir; Drug
Lead sponsor: Westat; Other
Eligibility: 16 Years and older · Female only
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 4
States / cities: Fort Lauderdale, Florida • New Orleans, Louisiana • Memphis, Tennessee + 1 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept, Background PAH Therapy; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Aurora, Colorado • Kansas City, Kansas • Albuquerque, New Mexico

Conditions: Colorectal Neoplasms
Interventions: 5-fluorouracil, bevacizumab, capecitabine, irinotecan, folinic acid, oxaliplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 45
States / cities: Mobile, Alabama • Long Beach, California • Los Angeles, California + 41 more

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Carboplatin, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Therapeutic Conventional Surgery; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Interventions: FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg, Placebo FDC, Placebo macitentan, Placebo tadalafil; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 26
States / cities: Fullerton, California • Los Angeles, California • Atlanta, Georgia + 22 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, Cobimetinib, Vemurafenib, Bevacizumab, Divarasib, Docetaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 12
States / cities: Sacramento, California • Denver, Colorado • Fort Myers, Florida + 9 more

Search by objective public record fields.

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)